TRIPLE THREAT TECHNOLOGY
Enlyton has developed ENL210 (an anti-TAG-72 humanized monoclonal antibody fragment) as a cancer-specific targeting agent for:
1. SPECT/CT imaging
2. Intraoperative imaging
3. Intraoperative detection.
Enlyton expects to enter clinical trials with ENL210 in early 2017.